X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA AJANTA PHARMA NATCO PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 16.4 20.7 79.0% View Chart
P/BV x 17.6 4.9 362.5% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
AJANTA PHARMA
Mar-18
NATCO PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs8771,818 48.2%   
Low Rs4241,106 38.3%   
Sales per share (Unadj.) Rs223.4239.5 93.3%  
Earnings per share (Unadj.) Rs31.152.8 58.8%  
Cash flow per share (Unadj.) Rs40.359.5 67.7%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.5230.0 95.4%  
Shares outstanding (eoy) m33.0788.77 37.3%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.96.1 47.7%   
Avg P/E ratio x20.927.7 75.6%  
P/CF ratio (eoy) x16.124.6 65.7%  
Price / Book Value ratio x3.06.4 46.6%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,504129,782 16.6%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m1,1283,765 30.0%   
Avg. sales/employee Rs ThNM3,128.4-  
Avg. wages/employee Rs ThNM554.0-  
Avg. net profit/employee Rs ThNM689.7-  
INCOME DATA
Net Sales Rs m7,38921,258 34.8%  
Other income Rs m167242 69.2%   
Total revenues Rs m7,55621,499 35.1%   
Gross profit Rs m1,7936,584 27.2%  
Depreciation Rs m304596 51.1%   
Interest Rs m3664 8,931.7%   
Profit before tax Rs m1,2906,226 20.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,539 20.1%   
Profit after tax Rs m1,0274,686 21.9%  
Gross profit margin %24.331.0 78.4%  
Effective tax rate %23.924.7 96.8%   
Net profit margin %13.922.0 63.1%  
BALANCE SHEET DATA
Current assets Rs m3,68112,236 30.1%   
Current liabilities Rs m3,1233,461 90.2%   
Net working cap to sales %7.641.3 18.3%  
Current ratio x1.23.5 33.3%  
Inventory Days Days8960 148.6%  
Debtors Days Days5984 69.5%  
Net fixed assets Rs m7,68511,140 69.0%   
Share capital Rs m331177 186.9%   
"Free" reserves Rs m6,67020,237 33.0%   
Net worth Rs m7,25920,414 35.6%   
Long term debt Rs m95510 9,454.5%   
Total assets Rs m11,95724,486 48.8%  
Interest coverage x4.51,519.4 0.3%   
Debt to equity ratio x0.10 26,588.5%  
Sales to assets ratio x0.60.9 71.2%   
Return on assets %11.719.2 60.8%  
Return on equity %14.223.0 61.7%  
Return on capital %20.730.5 67.9%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44511,667 29.5%   
Fx outflow Rs m7031,616 43.5%   
Net fx Rs m2,74310,052 27.3%   
CASH FLOW
From Operations Rs m1,4402,854 50.5%  
From Investments Rs m-1,089-2,604 41.8%  
From Financial Activity Rs m-353-2 17,635.0%  
Net Cashflow Rs m-1248 -0.6%  

Share Holding

Indian Promoters % 52.0 73.8 70.5%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 1.6 505.8%  
FIIs % 16.6 7.6 218.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.0 152.9%  
Shareholders   25,395 20,968 121.1%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Flat; Pharma Stocks Gain(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.5% while the Hang Seng is up 1%.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 26, 2018 10:11 AM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS